|
Market Closed -
Nasdaq
07:00:00 06/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 3.770 USD | +5.31% |
|
-7.14% | +134.16% |
| 17/08 | B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating | MT |
| 14/08 | MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MACROGENICS, INC. | Bio Therapeutic Drugs | +5.31% | -7.14% | +134.16% | +111.80% | -81.21% | 240M |  |  |  |
- Stock Market
- Stocks
- MGNX Stock
- Charts MacroGenics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
